Answers are grounded in this paper and cite their sources.
Review reveals high survival with retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia, highlighting the success of chemotherapy-free targeted protocols.
Acute promyelocytic leukemia (APL) represents a paradigm of precision medicine. Indeed, in the last decades, the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) completely revolutionized the therapeutic approach to this previously highly fatal disorder. This entirely chemotherapy-free treatment, which provided excellent survival rates, has been initially validated in adults and, recently, translated in the pediatric setting. This review summarizes currently available data on the use of ATRA and ATO combination in pediatric APL, providing a particular focus on peculiar issues and challenges, such as the occurrence of pseudotumor cerebri and death during induction (early death), as well as the advantage offered by the ATO/ATRA combination in sparing long-term sequelae.
No takes yet. Share an insight, caveat, or question.
Gurnari et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: